Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Engineered T-Cells Shown Reducing Non-Hodgkin Lymphoma

A clinical trial testing synthetic immune system cells shows after 6 months the cells can generate a full or partial response in many patients with non-Hodgkin lymphoma. . . . → Read More: Engineered T-Cells Shown Reducing Non-Hodgkin Lymphoma

Trial Begins Testing Enhanced Cord Blood Stem Cells

A clinical trial testing transplant grafts derived from umbilical cord blood as an alternative to bone marrow stem cells for people with blood-related cancers is treating its first patient. . . . → Read More: Trial Begins Testing Enhanced Cord Blood Stem Cells

Duchenne Gene-Editing Company Launched, Raising $5M

A biotechnology start-up is applying a process for editing-out disease-causing mutations to correct the inherited disorder Duchenne muscular dystrophy. . . . → Read More: Duchenne Gene-Editing Company Launched, Raising $5M

Genome Editing Builds Viral Disease Resistance in Pigs

Veterinary researchers used Crispr-Cas9, an emerging genome editing technique, to produce pigs with cells resistant to a common viral disease affecting commercial herds. . . . → Read More: Genome Editing Builds Viral Disease Resistance in Pigs

Nuclear Cancer Therapy Company Launches, Raises $25M

A new company developing cancer therapies combining nuclear radiation and synthetic antibodies is starting up in Hamilton, Ontario. . . . → Read More: Nuclear Cancer Therapy Company Launches, Raises $25M

Patent Issued for Peptides in Diabetes Gene Therapy

A U.S. patent was issued today for synthetic peptides that support gene therapies developed to treat type 2 diabetes and heart failure. . . . → Read More: Patent Issued for Peptides in Diabetes Gene Therapy

Patent Office Decides for Broad and Editas in Crispr Case

The U.S. Patent and Trademark Office decided that the gene editing processes developed by Broad Institute and licensed to Editas Medicine do not interfere with techniques for genome editing created by University of California at Berkeley. . . . → Read More: Patent Office Decides for Broad and Editas in Crispr Case

Tissue Regeneration Start-Up Gains $33M in Early Funds

A new enterprise founded by researchers at Stanford University aims to discover and develop drugs that repair and regenerate tissue from stem cells. . . . → Read More: Tissue Regeneration Start-Up Gains $33M in Early Funds

Biotech Group Withholds Support for Germline Trial Report

A biotechnology industry association in the U.S. says its members are not ready to support recommendations in a new report permitting future clinical studies of genome editing for inheritable disease-causing traits. . . . → Read More: Biotech Group Withholds Support for Germline Trial Report

Cancer Drug Shown to Improve Survival Time in Dogs

A drug to treat a deadly cancer in dogs was shown in a clinical trial to extend the survival time of canine patients by 6 months or more, with potential applications in humans. . . . → Read More: Cancer Drug Shown to Improve Survival Time in Dogs